Addition of elotuzumab ups PFS in refractory multiple myeloma

November 8, 2018

(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody elotuzumab in addition to pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone, according to a study published in the Nov. 8 issue of the New England Journal of Medicine.

Meletios A. Dimopoulos, M.D., from the National and Kapodistrian University of Athens in Greece, and colleagues randomly assigned 117 with that was refractory or relapsed and refractory to lenalidomide and a to receive either elotuzumab plus pomalidomide and dexamethasone (elotuzumab group, 60 patients) or pomalidomide and alone (control, 57 patients).

The researchers found that median progression-free survival was 10.3 and 4.7 months in the elotuzumab and control groups, respectively, after a minimum follow-up period of 9.1 months. Compared with the control group, the hazard ratio for disease progression or death was 0.54 in the elotuzumab group. The overall response rate was 53 and 26 percent in the elotuzumab and control groups, respectively (odds ratio, 3.25). Neutropenia, anemia, and hyperglycemia were the most common grade 3 or 4 adverse events.

"The results thus far are encouraging, but extended follow-up is warranted to determine long-term efficacy and safety outcomes, including the final analysis of overall survival," the authors write.

The study was funded by Bristol-Myers Squibb and AbbVie, the manufacturers of elotuzumab.

Explore further: Chemo combination promising for multiple myeloma

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Elotuzumab in multiple myeloma: Added benefit not proven

September 1, 2016
The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. ...

Ixazomib ups progression-free survival in multiple myeloma

April 28, 2016
(HealthDay)—For patients with relapsed, refractory, or relapsed and refractory multiple myeloma, ixazomib is associated with prolonged progression-free-survival, according to a study published in the April 28 issue of the ...

Immune approach is new tool against multiple myeloma cancer

May 13, 2015
A new kind of immune therapy has shown promise against the third most common blood cancer, multiple myeloma, researchers said Wednesday.

New drug shows potential for blood cancer

June 2, 2015
(HealthDay)—A two-pronged immune-boosting drug could provide new hope for people stricken with multiple myeloma, a cancer of the blood and bone marrow, according to clinical trial findings.

New myeloma treatment options show promise

September 4, 2014
(HealthDay)—New multiple myeloma treatment options appear promising for patients aged 65 years and younger and for newly diagnosed patients who are ineligible for stem-cell transplantation, according to two studies published ...

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.